

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## UMP HEALTHCARE HOLDINGS LIMITED

### 聯合醫務集團有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 722)**

### **INSIDE INFORMATION PROFIT WARNING**

This announcement is made by UMP Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the Group’s latest unaudited consolidated management accounts for the six months ended 31 December 2023 (“**Interim Period 2023/24**”), despite there was a mild increase in revenue, the unaudited consolidated profit attributable to owners of the Company is expected to be approximately HK\$15.0 million, a decrease of approximately 64.7% with reference to the unaudited consolidated profit attributable to owners of the Company of HK\$42.5 million for the six months period ended 31 December 2022 (“**Interim Period 2022/23**”).

The decrease in the unaudited consolidated profit attributable to owners of the Company was mainly attributable to the following factors:

- (1) an increase in the cost of service including the professional services expenses and cost of inventories consumed during the Interim Period 2023/24 compared to the Interim Period 2022/23;

- (2) an increase in human resources costs and rental charges mainly to complement the opening of two new imaging centres that have commenced business in February and May 2023 respectively and are currently in a ramping-up phase; and
- (3) an increase in depreciation charge in relation to the capital investment in medical equipment for the new medical and imaging centres.

The information contained in this announcement is only based on the preliminary assessment made by the Board with reference to the latest unaudited consolidated management accounts of the Group for the Interim Period 2023/24 and other information currently available to the Board, which have not been reviewed by the auditor of the Company. Further, the information in this announcement is not based on any figures or information reviewed or approved by the audit committee of the Board. The Company is still in the process of finalising its unaudited condensed consolidated results for the Interim Period 2023/24, which are subject to possible adjustments upon further review. The unaudited condensed interim results of the Group for the Interim Period 2023/24 are expected to be published by the end of February 2024.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**UMP Healthcare Holdings Limited**  
**Cheung Chi Wah, Patrick**  
*Company Secretary*

Hong Kong, 9 February 2024

*As at the date of this announcement, the Executive Directors of the Company are Dr. SUN Yiu Kwong (Chairman), Dr. SUN Man Kin, Michael (Vice-chairman and Co-Chief Executive Officer), Ms. KWOK Cheuk Kwan, Jacquen (Co-Chief Executive Officer), Mr. TSANG On Yip, Patrick, Dr. LEE Pak Cheung, Patrick; the Non-executive Director is Dr. LEE Kar Chung, Felix; and the Independent Non-executive Directors are Mr. LEE Luen Wai, John, Dr. LI Kwok Tung, Donald and Mr. YEUNG Tak Bun.*